藥明康德AH股齊跌 此前發佈95億港元股權激勵方案
格隆匯8月12日丨藥明康德AH股齊跌今日再度明顯下跌,A股跌超5%至135.49元,創近2個月新低,H股跌近5%至155.6港元,創7月28日以來新低;總市值3981億人民幣。藥明康德8月2日晚發佈新股權激勵草案:1)2021年H股獎勵信託計劃(草案):當2021年收入YOY達到34%以上,方案生效。H股獎勵信託計劃不超過20億港幣,分4年每年25%歸屬。2)2021年股東利益一致性獎勵計劃(草案):H股市價合共五年的任何12個月期間,有45個營業日或以上高於170港元、187港元、204港元和238港元,分別按10億、15億、20億及30億港元設立4個獎勵池,按照5年每期20%歸屬。業內分析人士稱,新股權激勵草案沒有挑戰性,上市公司淨利潤卻要被費用攤銷侵蝕。加上藥明康德股東之前一直在減持,情緒積壓致近期股價整體走弱。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.